Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) announced a private placement of not more than 59,880,235 on January 6, 2016. The transaction was approved by the China Securities Regulatory Commission. The transaction is subject to a hold period of 36 months expiring May 6, 2019.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.38 CNY | -1.60% |
|
-3.63% | +36.65% |
05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
04-25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.65% | 1.85B | |
+9.94% | 4.99B | |
-32.21% | 3.61B | |
-1.43% | 3.1B | |
-25.09% | 2.64B | |
-11.46% | 2.32B | |
+37.15% | 1.43B | |
-16.01% | 1.39B | |
+40.95% | 1.37B | |
-26.42% | 1.3B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Henan Lingrui Pharmaceutical Co., Ltd. announced that it expects to receive funding